EUVIMEDEUVIMED entdecken
Open Access

Association Between the CEP72 Genotype and Chemotherapy-Induced Peripheral Neuropathy Severity in Young Adults Receiving Vincristine or Paclitaxel

Robert Knoerl, Emanuele Mazzola, Maria F Pazyra-Murphy, Lindsay Frazier, Roy Freeman, Marilyn J Hammer, Ann S LaCasce, Jennifer Ligibel, Marlise R Luskin, Donna L Berry, Rosalind A Segal

Oncology Nursing Forum · 2025

DOI: 10.1188/25.onf.323-329 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Oncology Nursing Forum, 2025. Verfasst von Robert Knoerl und 10 weiteren Autor:innen. Beteiligte Einrichtung: Robert Knoerl. Hauptthemen laut MEDLINE: Paclitaxel, Vincristine, Peripheral Nervous System Diseases, Neoplasms. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NINR NIH HHS, NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: To determine the relationship between chemotherapy-induced peripheral neuropathy (CIPN) severity and centrosomal protein 72 (CEP72) genotype in young adults receiving paclitaxel or vincristine. SAMPLE & SETTING: 50 young adults aged 21-39 years who were expected to receive a cumulative dose of at least 7 mg vincristine or 700 mg/m2 paclitaxel for the treatment of cancer were recruited from Dana-Farber Cancer Institute. METHODS & VARIABLES: Participants completed a CIPN assessment tool and provided a blood sample before the first infusion. Participants completed the assessment tool at two additional time points. DNA was genotyped for CEP72 rs924607. CIPN scores were compared between those with the TT versus the CC or CT genotype over time using linear mixed-effects models. RESULTS: Young adults receiving vincristine with the TT CEP72 genotype experienced higher CIPN severity by the final time point, but the differences were not statistically significant (p > 0.05). IMPLICATIONS FOR NURSING: Future work to validate biomarkers like CEP72 may allow clinicians to identify patients who may benefit from altered chemotherapy dosages relative to CIPN risk.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PaclitaxelVincristinePeripheral Nervous System DiseasesNeoplasmsMicrotubule-Associated ProteinsAntineoplastic Agents, PhytogenicAntineoplastic AgentsHumansAdultFemaleMaleYoung AdultGenotypeSeverity of Illness Index

Stichwörter der Autor:innen

CEP72chemotherapy-induced peripheral neuropathygenotypeneoplasmsyoung adult

Substanzen

PaclitaxelVincristineCEP72 protein, humanMicrotubule-Associated ProteinsAntineoplastic Agents, PhytogenicAntineoplastic Agents

Autor:innen und Institutionen

  • Robert Knoerl.
  • Emanuele Mazzola.
  • Maria F. Pazyra-Murphy.
  • Lindsay Frazier.
  • Roy Freeman.
  • Marilyn J. Hammer.

Förderung

  • NINR NIH HHS
  • NCI NIH HHS

Zitieren

APA

Knoerl, R., Mazzola, E., Pazyra-Murphy, M. F., Frazier, L., Freeman, R., Hammer, M. J., LaCasce, A. S., Ligibel, J., Luskin, M. R., Berry, D. L., & Segal, R. A. (2025). Association Between the CEP72 Genotype and Chemotherapy-Induced Peripheral Neuropathy Severity in Young Adults Receiving Vincristine or Paclitaxel. Oncology Nursing Forum. https://doi.org/10.1188/25.onf.323-329

Vancouver

Knoerl R, Mazzola E, Pazyra-Murphy MF, Frazier L, Freeman R, Hammer MJ, et al. Association Between the CEP72 Genotype and Chemotherapy-Induced Peripheral Neuropathy Severity in Young Adults Receiving Vincristine or Paclitaxel. Oncology Nursing Forum. 2025. doi:10.1188/25.onf.323-329

BibTeX
@article{Knoerl2025,
  author = {Knoerl, Robert and Mazzola, Emanuele and Pazyra-Murphy, Maria F and Frazier, Lindsay and Freeman, Roy and Hammer, Marilyn J and LaCasce, Ann S and Ligibel, Jennifer and Luskin, Marlise R and Berry, Donna L and Segal, Rosalind A},
  title = {Association Between the CEP72 Genotype and Chemotherapy-Induced Peripheral Neuropathy Severity in Young Adults Receiving Vincristine or Paclitaxel},
  journal = {Oncology Nursing Forum},
  year = {2025},
  doi = {10.1188/25.onf.323-329}
}
Kostenlos starten →